Palika Datta1, Andrea I Ciplea2, Kathleen Rewers-Felkins1, Teresa Baker3, Ralf Gold4, Thomas W Hale1, Kerstin Hellwig4. 1. Department of Pediatrics, Texas Tech University Health Sciences Center, Amarillo, TX, USA. 2. Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany/Institute of Clinical Pharmacy and Pharmacotherapy, Heinrich Heine University Düsseldorf, Düsseldorf, Germany. 3. Department of Obstetrics and Gynecology, Texas Tech University Health Sciences Center, Amarillo, TX, USA. 4. Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.
Abstract
BACKGROUND: Cladribine is an antimetabolite used for the treatment of relapsing-remitting multiple sclerosis. At present, there are no data available on its use in breastfeeding mothers and its transfer in human milk. OBJECTIVE: We present a case of a lactating mother who donated her milk samples to study the transfer of cladribine following a 20-mg oral dose. METHODS: Analysis was done using liquid chromatography-mass spectrometry. RESULTS: The relative infant dose calculated in this study was 3.06%. CONCLUSION: This is the first case report suggesting the transfer of cladribine in human milk in measurable quantities. However, caution should be advised during lactation.
BACKGROUND:Cladribine is an antimetabolite used for the treatment of relapsing-remitting multiple sclerosis. At present, there are no data available on its use in breastfeeding mothers and its transfer in human milk. OBJECTIVE: We present a case of a lactating mother who donated her milk samples to study the transfer of cladribine following a 20-mg oral dose. METHODS: Analysis was done using liquid chromatography-mass spectrometry. RESULTS: The relative infant dose calculated in this study was 3.06%. CONCLUSION: This is the first case report suggesting the transfer of cladribine in human milk in measurable quantities. However, caution should be advised during lactation.
Authors: Fioravante Capone; Angela Albanese; Giorgia Quadri; Vincenzo Di Lazzaro; Emma Falato; Antonio Cortese; Laura De Giglio; Elisabetta Ferraro Journal: Front Neurol Date: 2022-04-15 Impact factor: 4.003